Cartesian Therapeutics, Inc.
No SEC Form 4 filings for $RNAC in the last 30 days.
Needham & Company lowered its Cartesian Therapeutics (NASDAQ: RNAC) price target to $40 from $42 while keeping a “buy” rating, according to a Tuesday note reported by Benzinga. RNAC traded at $6.38, down 5.5%. The company reported Q1 EPS of -$1.46 and revenue of $0.08M, missing consensus.
Murat Kalayoglu is resigning from Cartesian's Board of Directors, effective March 31, 2026, to pursue other opportunities. He will also cease serving on the Science and Technology Committee and the Nominating and Corporate Governance Committee. Kalayoglu has been on the board since 2023.
Cartesian Therapeutics, Inc. announced the granting of inducement awards to two new employees. These awards include options to purchase an aggregate of 12,050 shares of the Company's common stock at an exercise price of $6.79. The options will vest over four years, with the first 25% vesting on February 2, 2027, and the remainder vesting in monthly installments.
